Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Priority to UY28102ApriorityCriticalpatent/UY28102A1/en
Publication of UY28102A1publicationCriticalpatent/UY28102A1/en
Se proporcionan sales de adición de ácido farmacéuticamente aceptables de compuestos de fórmula I, en donde R1 representa alquilo C1-2 sustituido por uno o más sustituyentes fluoro; R2 representa alquilo C1-2; y n representa 0, 1 ó 2, las cuales son útiles como profármacos de inhibidores competitivos de proteasas similares a la tripsina, tales como la trombina y, de esta forma, en particular, en el tratamiento de afecciones en las que es necesario inhibir la trombina (por ej. trombosis) o como anticoagulantes.Pharmaceutically acceptable acid addition salts of compounds of formula I are provided, wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents C1-2 alkyl; and n represents 0, 1 or 2, which are useful as prodrugs of competitive inhibitors of trypsin-like proteases, such as thrombin and, in this way, in particular, in the treatment of conditions in which it is necessary to inhibit thrombin (eg thrombosis) or as anticoagulants.
COMPOUNDS DERIVED FROM CARBOXILIC ACIDS, ITS SALTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION, AND ITS USE IN THE TREATMENT OF DISEASES WHERE AN INHIBITOR OF THE FACTOR Xa AND / OR AN INHIBITOR OF SERINA PROTEASA IS NECESSARY.